idrabiotaparinux
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute…
Summary. Background: Idraparinux, a long acting inhibitor of factor (F) Xa, is as effective as standard anticoagulant therapy…
The therapeutic armamentarium of parenteral anticoagulants available to clinicians is mainly composed by unfractionated heparin…
Summary. Background: Idraparinux is an inhibitor of activated factor X (FXa) with a long half‐life allowing once‐weekly dosing…
Idraparinux is a polymethylated synthetic pentasaccharide that binds to antithrombin with high affinity. Idrabiotaparinux is a…
Over the last 15 years, there has been a shift from unfractionated heparin to low-molecular-weight heparin or fondaparinux for…
Idraparinux is an analogue of fondaparinux binding with high affinity to antithrombin. It was designed for weekly, rather than…
Anticoagulation is recommended for prophylaxis and treatment of venous thromboembolism (VTE) (deep vein thrombosis and pulmonary…
Idrabiotaparinux is a novel synthetic anticoagulant that links idraparinux, a specific, indirect factor Xa inhibitor, to biotin…